Market: OTC-BB
Current Price: 0.95 +0.03

Free trading issued: 20,500,000
Restricted issued: 25,000,000

Total issued: 45,500,000
Available to issue: 54,500,000
Authorized Shares: 100,000,000 common/100,000,000 preferred

IR Toll Free: 1-877-331-8777

CUSIP #: 00830E 105
Year end: 09/30
Incorporation date: June 21, 2006
Incorporated in: Nevada

Officers: Mr. Richard Azani, CEO

News Archive

A5 Laboratories has received approval letter for it’s containment level 2 facility.

February 3rd, 2011

A5 Laboratories, Inc. Announces Successful Production of VI-1718 Interferon Product

February 1st, 2011

A5 Laboratories Inc Provides Operational Update

January 19th, 2011

A5 Laboratories Inc. Retains Barwicki Investor Relations

December 29th, 2010

A5 Laboratories Inc. Announces Preparation of Initial VI-1718 Interferon Product

December 2nd, 2010

A5 Laboratories Inc. Completes Validation of Its CRO Laboratory Information Management System (LIMS)

November 10th, 2010

A5 Laboratories Inc. Expands Management for the Development of Interferon Projects

November 8th, 2010

A5 Laboratories Inc. Signs Partnership Agreement for the Production of Interferon Products

October 28th, 2010

A5 Laboratories Inc. Announces Additional CRO Customers

September 29th, 2010

A5 Laboratories Inc. Engages Mirador Consulting for Financial Advisory and Public Relations Representation

September 24th, 2010

A5 Laboratories Inc. Completes CRO Standard Operating Procedure Documentation

September 14th, 2010

A5 Laboratories Inc. Completes Validation of CRO Equipment

August 31st, 2010

A5 Laboratories Inc. Granted U.S. Provisional Patent Number US 61/400,719 for the Production of Interferon-Based Products

August 24th, 2010

A5 Laboratories Inc. Begins Operating Environmental Assessment Business

August 19th, 2010

A5 Laboratories Inc. Appoints Senior Managers

August 17th, 2010

A5 Laboratories Inc. Expands Board of Directors and Management Team

August 10th, 2010

A5 Laboratories Inc. Submits Provisional Patent Application

July 29th, 2010

A5 Laboratories Inc. Signs Analytical Services Contract With BioActif Inc.

July 20th, 2010

Acquisition of CRO Assets

July 15th, 2010

Agreement With a New CRO Customer

July 14th, 2010

A5 LABORATORIES INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Shell Company Status, Fina (EDGAR Online)

July 7th, 2010

A5 LABORATORIES INC. Financials (EDGAR Online Financials)

June 30th, 2010

A5 LABORATORIES INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit (EDGAR Online)

June 23rd, 2010

RETRANSMISSION: A5 Labs Signs Letter of Intent to Acquire CRO Assets and Interferon Technology (Marketwire)

May 7th, 2010

EL PALENQUE VIVERO, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulat (EDGAR Online)

April 8th, 2010

EL PALENQUE VIVERO, INC. Financials (EDGAR Online Financials)

April 1st, 2010